EX-10.1
from 10-Q
21 pages
Purchase Price: $1,450,000.00 Purchased Amount: $ 2,102,500.00 Average Projected Monthly Sales: $1,151,351.46 Specified Percentage: 15 % (Average Projected Monthly Sales X Specified Percentage / Average Business Days in a Calendar Month) Initial Weekly Amount: Please See Exhibit B-4 Origination Fee: $130,500.00 (To Be Deducted From the Purchase Price) Payment Will Be Withdrawn Every Thursday Account for the Deposit of All Future Receipts: Bank: US Bank Account No
12/34/56
EX-10.1
from 10-Q
21 pages
Purchase Price: $1,325,000.00 Purchased Amount: $1,908,000.00 Average Projected Monthly Sales: $2,085,904.68 Specified Percentage:15 % (Average Projected Monthly Sales X Specified Percentage / Average Business Days in a Calendar Month) Initial Weekly Amount: Please See Exhibit B-4 Origination Fee: $119,250.00 (To Be Deducted From the Purchase Price) Payment Will Be Withdrawn Every Monday Account for the Deposit of All Future Receipts: Bank: California Bank & Trust Account No
12/34/56
EX-10.48
from 10-K
24 pages
Purchase Price: $1,000,000.00 Purchased Amount: $1,475,000.00 Average Projected Monthly Sales: $2,184,074.62 Specified Percentage: 15 % (Average Projected Monthly Sales X Specified Percentage / Average Business Days in a Calendar Month) Initial Weekly Amount: Please See Exhibit B-4 Origination Fee: $90,000.00 (To Be Deducted From the Purchase Price) Payment Will Be Withdrawn Every Monday Account for the Deposit of All Future Receipts: Bank: California Bank & Trust Account No
12/34/56
EX-10.1
from 10-Q
21 pages
Purchase Price: $880,000.00 Purchased Amount: 1,298,000.00 Average Projected Monthly Sales: $2,231,558.83 Specified Percentage: 15 % (Average Projected Monthly Sales X Specified Percentage / Average Business Days in a Calendar Month) Initial Weekly Amount: Please See Exhibit B-4 Origination Fee: $80,000.00 (To Be Deducted From the Purchase Price) Payment Will Be Withdrawn Every Monday Account for the Deposit of All Future Receipts: Bank: California Bank & Trust Account No
12/34/56
EX-10.2
from 8-K
1 page
This Joinder Areement and Amendment to Transfer Restriction and Voting Agreement (This “Agreement”) Is Made With Reference to the Transfer Restriction and Voting Agreement (The “Voting Agreement”) Made and Entered Into as of February 8, 2021 by and Among Between Emmaus Life Sciences, Inc., a Delaware Corporation (The “Company”), and Each Purchaser Identified on the Purchaser Signature Pages Thereto (Each, Including Its Successors and Permitted Assigns, the “Purchaser”), With Reference to the Following Facts: Wheras, the Undersigned Investor Is a Successor and Assign of One or More of the “Convertible Notes” Referred to in the Voting Agreement; And
12/34/56
